These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9723101)

  • 1. [Pharmacologic treatment of dyslipidemias: Analysis of initiation recommendations and drug selection].
    Davidoff P
    Rev Med Chil; 1991 Dec; 119(12):1423-32. PubMed ID: 9723101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
    Yeshurun D; Hamood H; Morad N; Naschitz J
    Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia.
    Fogari R; Marasi G; Vanasia A; Zoppi A; Lusardi P; Preti P
    Int J Clin Pharmacol Ther; 1997 Feb; 35(2):61-4. PubMed ID: 9147709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acipimox in primary hyperlipidemias: safety and efficacy evaluated in six months].
    Davidoff P; Ruiz F; Varas MA; García de los Ríos M; Silva MA; González G; Tapia JC
    Rev Med Chil; 1991 Oct; 119(10):1140-6. PubMed ID: 1845208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1997 Feb; 241(2):151-5. PubMed ID: 9077372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1998 May; 243(5):151-6. PubMed ID: 9651568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia].
    Tonutti L; Taboga C; Noacco C
    Minerva Med; 1991 Oct; 82(10):657-63. PubMed ID: 1745376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hyperlipidemia: goals for the prevention of atherosclerosis.
    Illingworth DR
    Clin Invest Med; 1990 Aug; 13(4):211-8. PubMed ID: 2208837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating hyperlipidemia, Part III: Drug therapy.
    Smith DA; Karmally W; Brown WV
    Geriatrics; 1987 Aug; 42(8):55-9, 62. PubMed ID: 3110017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M; Montali A; Pigna G; Antonini R; Antonini TM; Luigi P; Fraioli A; Mastrantoni M; Maddaloni M; Letizia C
    Metabolism; 2007 Nov; 56(11):1534-41. PubMed ID: 17950105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacologic treatment of lipid metabolism disorders].
    Gmiński J
    Wiad Lek; 1996; 49(7-12):173-81. PubMed ID: 9214849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of dyslipidemia in the high-risk patient.
    Stein EA
    Am Heart J; 2002 Dec; 144(6 Suppl):S43-50. PubMed ID: 12486415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug treatment of hyperlipidemia].
    Zazgornik J; Koch S
    Wien Med Wochenschr Suppl; 1989; 105():20-3. PubMed ID: 2694628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hyperlipidemia: therapeutic principles in clinical practice].
    Müller-Wieland D; Krone W
    Med Klin (Munich); 2003 Dec; 98(12):739-43. PubMed ID: 14685674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.